Burges Salmon advises PlaqueTec on $5m investment raise
Bristol-headquartered law firm Burges Salmon has advised medtech company PlaqueTec on a $5m investment fundraise.
PlaqueTec, which is based in Cambridge, is developing intracoronary liquid biopsy technologies designed to improve understanding and treatment of cardiovascular disease.
The funding round was oversubscribed and backed entirely by the company’s existing shareholders.
The investment will support the continued development of PlaqueTec’s proprietary cardiovascular disease data platform, BioCarta™.
The platform is a growing repository of intracoronary proteomic and clinical data, designed to help inform more precise patient stratification and support the development of targeted therapeutic programmes for cardiovascular disease.
PlaqueTec’s technology allows proteomic biomarkers to be assessed at the site of coronary plaque formation. The company said this generates insights that cannot be obtained through conventional systemic blood tests.
Data generated through PlaqueTec’s ongoing BIOPATTERN clinical trial is already identifying novel inflammatory drivers across key patient sub-groups.
The company said this positions BioCarta as a differentiated asset for future partnership, licensing and therapeutic development opportunities.
Burges Salmon’s Corporate and M&A team advised PlaqueTec on the fundraise.
The team was led by senior associate Katie Carter, partner Alex Lloyd and solicitor Sophie Dicks.
Katie Carter, senior associate at Burges Salmon, said:
PlaqueTec is building a genuinely differentiated data asset at the intersection of cardiovascular research, clinical insight and therapeutic development. This successful fundraise is a strong endorsement of both the company’s technology and its long-term strategy.
We’re pleased to have supported PlaqueTec on this important milestone and look forward to seeing the BioCarta platform continue to gain momentum.
Mark Ebner, head of finance at PlaqueTec, said the investment reflected confidence in the company’s approach.
He said:
This successful raise underlines the confidence our shareholders have in PlaqueTec’s data-led approach to cardiovascular disease and the long-term potential of the BioCarta platform.
We’re grateful to Alex, Katie, Sophie and the Burges Salmon team for their outstanding support, sector insight and clear, commercial advice throughout the transaction.
